Biomarkers: Tool to identify the Women at increased stroke risk

The Women's Health Initiative hormone trials identified a 44% increase in ischemic stroke risk with combination estrogen plus progestin and a 39% increase with estrogen alone. We undertook a case-control biomarker study to elucidate underlying mechanisms, and to potentially identify women who would be at lower or higher risk for stroke with postmenopausal hormone therapy (HT).

 

    Related Conference of Biomarkers: Tool to identify the Women at increased stroke risk

    July 14-15, 2025

    21st International Congress on Advances In Natural Medicines, Nutraceuticals & Neurocognition

    Berlin, Germany
    September 08-09, 2025

    24th World Congress on Nutrition and Food Chemistry

    Frankfurt, Germany
    September 15-16, 2025

    29th World Congress on Nutrition and Food Sciences

    Paris, France
    November 13-14, 2025

    18th World Congress on Food Chemistry and Food Microbiology

    Bali, Indonesia
    December 08-09, 2025

    8th World Congress on Food and Nutrition

    Rome, Italy
    January 29-30, 2026

    30th International Conference on Nutritional Science & Dietetics

    Chicago, USA
    March 19-20, 2026

    25th International Conference on Diabetes, Nutrition, Obesity and Eating Disorders

    Paris, France
    April 02-03, 2026

    31st International Conference on Nutrition & Dietetics

    Geneva, Switzerland

    Biomarkers: Tool to identify the Women at increased stroke risk Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in